PolitiKit

Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs

Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders.

Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Advancing adoption of AI in the healthcare and health research sectors.

Advancing Canada’s health research and innovation agenda as it relates to funding, policy and program design, and regulatory matters, including in the areas of clinical trials and development of innovative medical treatments.

Federal role in the health system as it relates to funding, the use of federal spending power, and pan-Canadian priorities, including in the areas of aging, older adult care, child and youth health, mental health and substance use, palliative care, Indigenous health, public health, and data.

Tobacco excise tax stamping requirements for smokeless tobacco products under the Excise Act, 2001 and related proposals and/or requirements to change or modify tax stamp requirements for smokeless tobacco.

Tobacco labeling in respect of plain packaging, trade-marks, health warnings, constituent reporting and labeling of same for smokeless tobacco products.

Tobacco taxation in respect of the Excise Act and manufactured tobacco taxes.

Nicotine pouch regulation in respect of legislative or regulatory proposals, bills, or resolutions under or related to the Food and Drugs Act/Natural Health Products Regulations.

Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing.

Consultation on the National Strategy on mental health of men and boys

Discussions related to Bill S-5 Connected Care for Canadians Act.

Invest in family medicine by adding new family doctors and directing funding to expand training, have fair compensation, and other recruitment/retention measures.

Connected Care for Canadians Act (BILL S-5) : Urging federal policy makers to adopt this legislation quickly and to ensure that it is supported by a robust set of regulations.

Support family doctors with teams, as that is a key enabler to providing high quality primary care

Funds should be directed to supporting family practices, as part of the Federal government's Health Infrastructure Fund announced in Budget 2025.

Free trade agreements as they relate to the biopharmaceutical industry.

Advocate for the implementation of a federal diabetes and obesity strategy.

We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).

Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities

Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

Arranging meetings for the client to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

Support for regulated nurses working at full scope of practice

Support the development of a national licensure framework for nurses.

Create a pan-Canadian health human resources strategy

Discussions aim to ensure that artificial intelligence and emerging health technologies are developed, assessed, and approved in ways that meet the needs of the Canadian population. Communications emphasize the importance of integrating nursing perspectives into governance, regulation, clinical and ethical evaluation, and approval processes for new technologies.

Allow nurses to certify the Disability Tax Credit form

Clinical decision support: Support the national integration of Clinical Decision Support (CDS) systems into electronic medical records (EMRs) to ensure that patients receive the right test at the right time.

Artificial Intelligence: Demonstrate leadership in AI by providing financial support for the Health Artificial Intelligence Validation Network (HAIVN) to improve the evaluation and regulation of AI in Canada as part of Health Canada’s Medical Devices Directorate regulatory process, for the purpose of improved healthcare, economic development and innovation in Canada.

Capital equipment (CT and MRI): Guide a dedicated investment of $2 billion over three years for radiology equipment to improve access to modern medical imaging equipment. Streamline the process for equipment installation and reduce the substantial associated labour costs.

HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act.

INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care.

TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed.

FEDERAL HEALTH FUNDING FOR A NEW PRIMARY CARE ACCESS FUND: Recommendation for a funding commitment to ensure that every Canadian has access to a family doctor or primary care team.

HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act.

FEDERAL HEALTH FUNDING FOR A NEW PRIMARY CARE ACCESS FUND: Recommendation for a funding commitment to ensure that every Canadian has access to a family doctor or primary care team.

TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed.

MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts.

Federal investments to improve support for the pharmacy workforce

E-health specifically as it relates to the implementation of e-prescribing in Canada, including funding for Canada Infoway

Prioritizing immigration of health care workers

Foreign Credential recognition Program, Health Canada Health Human Resources (HHR) Strategy - working with the department to understand the entry of foreign-trained pharmacists to Canada

Taxation, revenue measures, controlled products regulations, including implementation, for alcohol, tobacco control, products containing carcinogens and products associated with cancer.

Tobacco and Vaping Products Act, as it relates to regulations, implementation and enforcement

Financial supports for caregivers, including the Canada Caregiver Credit

Implementation of the Framework on Palliative Care in Canada and integration of a palliative approach to care in our health system, including national standards and data, care provider training, research, and implementation of the National Grief Action Plan and distinctions?based frameworks for First Nations, Inuit and Métis people

Food and Drugs Act and regulations, as it relates to nciotine replacement products

Approvals process for the launch of clinical trials in Canada including regulation, funding, the creation of intellectual property and commercialization in Canada for the purpose of pharmaceutical sovereignty, economic development and scientific innovation.